Validation study for cervical HPV and dysplasia screening test

PRINCIPAL INVESTIGATOR:
PD Dr. Andreas Kaufmann
Charité

SUMMARY

The team has developed a diagnostic test for cervical HPV infection and dysplasia detection with high sensitivity, specificity as well as a high positive predictive value. The initial use is in triaging of equivocal screening findings. Current tests like cytology and PCR-based HPV testing either lack diagnostic accuracy or require a biopsy in follow up. After patenting, the team is currently performing a clinical study. In the future, CE certification of the test and accreditation of a service lab are planned to bring the test to the patients. Cervical cancer is the second most common cancer in women living in low and middle income countries with more than half a million new cases in 2018. Due to lack in standard screening procedures the test could be used there as a screening tool.

PROJECT ACHIEVEMENTS DURING SPARK

• Developed a multiplexed quantitative mRNA-based test combining HPV and biomarker expression
• Developed algorithm to predict disease stage
• Patent filed in 2019
• Study conducted, analysis started

LONG-TERM GOALS

• Founding of a startup company in 2022
• CE certification of test
• Service lab accreditation

PREVIOUS SPARK FUNDING

• Track 1 2017